Literature DB >> 29893703

Urinary Neutrophil Gelatinase-Associated Lipocalin in Cirrhotic Patients with Acute Kidney Injury.

Hassan S Hamdy1, Ahmed El-Ray2, Mohamed Salaheldin1, Mohammad Lasheen2, Mohamed Aboul-Ezz2, Ahmed S Abdel-Moaty1, Ali Abdel-Rahim2.   

Abstract

INTRODUCTION AND AIM: It is well known that development of acute kidney injury (AKI) increases mortality in hospitalized cirrhotic patients; therefore many novel markers have been studied for early detection, differential diagnosis and prognosis in cirrhotic patients with AKI. The aim of the current work is to evaluate urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as a diagnostic biomarker for different causes of acute kidney injury in liver cirrhosis and to assess it as a prognostic marker.
MATERIAL AND METHODS: Out of 83 cirrhotic patients with AKI admitted between October 2015 and June 2016; 70 patients were included in this prospective study. Routine laboratory tests, uNGAL and fractional excretion of Na were obtained on admission. End points were death or improvement of kidney function and discharge.
RESULTS: The patients included in our study were 41 males and 29 females with mean age 54.27 ± 6.08 years. HCV was the etiology of cirrhosis in 69 cases while one had combined HBV and HCV infection. More than 50% of patients were classified as Child C. Causes of kidney injury were prerenal, hepatorenal syndrome (HRS) and intrinsic tubular injury (iAKI) in 39 patients (55.7%), 17 patients (24.3%) and 14 patients (20%) respectively. mean value of uNGAL in prerenal, HRS and iAKI was 21.70 ± 7.31, 115.53 ± 68.19 and 240.83 ± 116.94 ng/mg creatinine respectively. MELD above 20 and uNGL above 32 were predictors of mortality.
CONCLUSION: A single baseline measurement of uNGAL level has the ability to determine type of kidney dysfunction in cirrhotic patients, perhaps accelerating management decisions and improving outcomes.

Entities:  

Keywords:  Hepatorenal syndrome; Liver cirrhosis; NGAL; Urinary biomarkers

Mesh:

Substances:

Year:  2018        PMID: 29893703     DOI: 10.5604/01.3001.0012.0931

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  7 in total

Review 1.  Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis.

Authors:  Juan Carlos Q Velez; George Therapondos; Luis A Juncos
Journal:  Nat Rev Nephrol       Date:  2019-11-13       Impact factor: 28.314

Review 2.  Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy.

Authors:  Juan Carlos Q Velez
Journal:  Kidney360       Date:  2021-12-03

3.  Urinary Neutrophil Gelatinase-Associated Lipocalin Can Predict the Efficacy of Volume Expansion Therapy in Patients With Hepatitis B Cirrhosis and AKI.

Authors:  Zhonghui Duan; Minjie Jiang; Xiaojie Huang; Haixia Liu; Hongwei Yu; Qinghua Meng
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

4.  Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) for Prediction of Persistent AKI and Major Adverse Kidney Events.

Authors:  Nuttha Lumlertgul; Monpraween Amprai; Sasipha Tachaboon; Janejira Dinhuzen; Sadudee Peerapornratana; Stephen J Kerr; Nattachai Srisawat
Journal:  Sci Rep       Date:  2020-05-26       Impact factor: 4.379

5.  The clinical significance of neutrophil gelatinase-associated lipocalin in ischemic stroke patients with acute kidney injury.

Authors:  Wei Xiao; Wei Chen; Hanning Hu; Xiaomei Huang; Yi Luo
Journal:  J Clin Lab Anal       Date:  2019-05-07       Impact factor: 2.352

6.  Comparison of urinary TIMP-2 and IGFBP7 cut-offs to predict acute kidney injury in critically ill patients: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Dongquan Zhang; Yuan Yuan; Longfei Guo; Quanhong Wang
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

7.  The efficacy of biomarkers in the diagnosis of acute kidney injury secondary to liver cirrhosis.

Authors:  Yuwei Yang; Bin Ge; Yan Liu; Jiafu Feng
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.